logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Ionis and Alnylam Secured Their Future Prosperity

Ionis Pharmaceuticals Ionis Pharmaceuticals ( IONS ) announces a private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024. To read this news go to the original  content to download multimedia by clicking here .  During...

Read More

December 12, 2019

0

Exploring two clinical-stage firms with new, different approaches to treatments

SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO  Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in Phase 2 clinical trial for the treatment of localized prostate. The product is in Phase 3 clinical trial for lower urinary tract symptoms of...

Read More

June 27, 2018

0

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

CiRA, Takeda  & T-CiRA Less than five years ago the Center for iPS Cell Research and Application (CiRA) 1   at Kyoto University and Takeda   Pharmaceutical ( TAK ) 2 established a research program. Today, Takeda and CiRA announced...

Read More

July 17, 2019

0

Why Vertex added over $20 to its stock price today

Health Canada Approves PrSYMDEKO™ For People Ages 12 and Older With Certain CFTR Gene Mutations Vertex (VRTX) announced that Health Canada approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have...

Read More

June 29, 2018

0

Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Stock Rallied Seattle Genetics ( SGEN ) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following: Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting...

Read More

July 17, 2019

0

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

The New England Journal of Medicine ( NEJM ) published results from the CELESTIAL phase 3 pivotal trial of Exelixis (EXEL) product Cabometyx® ( cabozantinib) in previously treated patients with advanced hepatocellular carcinoma (HCC) . The data demonstrate that Cabometyx...

Read More

July 5, 2018

0

Amarin: The FDA Approves Vascepa for Lowering Cardiovascular Risk

From Amarin Amarin ( AMRN )  announced the U.S. FDA has approved a new indication and label expansion for Vascepa®  (icosapent ethyl) capsules. According to Amarin’s press release, with this label expansion approval, Vascepa has become the first and only FDA...

Read More

December 16, 2019

0

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities There is no doubt that  Gilead Sciences ( GILD )   is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and every week, we heard news...

Read More

July 22, 2019

0

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

The BLA Includes Data from More Than 11,000 Patients Amgen (AMGN) and UCB (Euronext Brussels: UCB) resubmitted a Biologics License Application (BLA) to the U.S. FDA for the approval of their osteoporosis investigational monoclonal antibody product Evenity™ (romosozumab). The product...

Read More

July 13, 2018

0

Once again, we say, CRISPR is here to stay

A Miracle-Like Gene-Editing That People will Sooner or Later Recognize . The Wellcome Sanger Institute’s new findings about CRISPR/Cas9 gene editing is intended to lead to further improvement in the safety of the breakthrough CRISPR gene editing procedure before it...

Read More

July 18, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 77
  • 78
  • 79
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy